Skip to main
NTRA

Natera (NTRA) Stock Forecast & Price Target

Natera (NTRA) Analyst Ratings

Based on 19 analyst ratings
Buy
Strong Buy 37%
Buy 53%
Hold 11%
Sell 0%
Strong Sell 0%

Bulls say

Natera is a rapidly growing company, with expanding product offerings and strong financial growth. Their recent achievements in developing blood tests for various diseases and gaining Medicare coverage show promise for further growth and profitability. Additionally, their partnerships and collaborations with other companies indicate a strong potential for future success.

Bears say

Natera is facing risks such as a potential decline in market share for its NIPT product and increased competition in the cancer recurrence monitoring market. Although the company raised its 2026 revenue and gross margin guides, they also increased their R&D spending to accelerate clinical studies for CRC screening, which may impact profitability. Furthermore, with other labs entering the large and underpenetrated MRD market, Natera may face challenges in proving the value of its tests and maintaining its first-mover advantage.

Natera (NTRA) has been analyzed by 19 analysts, with a consensus rating of Buy. 37% of analysts recommend a Strong Buy, 53% recommend Buy, 11% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Natera and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Natera (NTRA) Forecast

Analysts have given Natera (NTRA) a Buy based on their latest research and market trends.

According to 19 analysts, Natera (NTRA) has a Buy consensus rating as of Sep 14, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $328.66, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $328.66, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Natera (NTRA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.